CelLBxHealth plc (AIM:CLBX)
London · Delayed Price · Currency is GBP · Price in GBX 1.315
-0.010 (-0.75%)
Aug 17, 2026, 3:02 PM GMT
CelLBxHealth Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.15 | 1.35 | 2.86 | 2.19 | 1.04 | 1.01 | |
Revenue Growth | -56.10% | -52.80% | 30.92% | 109.99% | 2.76% | 32.94% |
Cost of Revenue | 1.49 | 1.58 | 1.89 | 2.59 | 1.2 | 0.96 |
Gross Profit | -0.33 | -0.23 | 0.97 | -0.41 | -0.16 | 0.05 |
Selling, General & Admin | 0.27 | 7.23 | 9.43 | 11.18 | 14.26 | 10.18 |
Research & Development | 1.28 | 1.28 | 1.77 | 2.48 | 4.04 | 2.91 |
Amortization of Goodwill & Intangibles | 0.07 | 0.07 | 0.13 | 0.07 | 0.98 | 0.23 |
Other Operating Expenses | 2.41 | 2.58 | 3.03 | 3.45 | 4.18 | 2.23 |
Operating Expenses | 7.38 | 14.51 | 15.93 | 19.41 | 25.32 | 16.79 |
Operating Income | -7.71 | -14.74 | -14.96 | -19.82 | -25.49 | -16.73 |
Interest Expense | -0.18 | -0.26 | -0.31 | -0.33 | -0.35 | -0.16 |
Interest & Investment Income | 0.08 | 0.13 | 0.4 | 0.46 | 0.14 | 0.03 |
Currency Exchange Gain (Loss) | -1.66 | -1.66 | 0.37 | -1.23 | 2.06 | 0.12 |
Other Non Operating Income (Expenses) | -0.61 | -0.61 | -0.51 | -0.64 | -0.62 | -0.59 |
EBT Excluding Unusual Items | -10.08 | -17.15 | -15.02 | -21.55 | -24.27 | -17.34 |
Impairment of Goodwill | -2.21 | -2.21 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.06 | -0.06 | -0.01 | -0.08 | -0.17 | -0 |
Asset Writedown | - | - | - | - | - | -0.02 |
Pretax Income | -12.35 | -19.41 | -15.03 | -21.63 | -24.44 | -17.36 |
Income Tax Expense | 0.6 | 0.1 | -0.8 | -1.5 | -2.75 | -2.35 |
Earnings From Continuing Operations | -12.94 | -19.51 | -14.23 | -20.13 | -21.69 | -15.01 |
Net Income to Company | -12.94 | -19.51 | -14.23 | -20.13 | -21.69 | -15.01 |
Net Income | -12.94 | -19.51 | -14.23 | -20.13 | -21.69 | -15.01 |
Net Income to Common | -12.94 | -19.51 | -14.23 | -20.13 | -21.69 | -15.01 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 761 | 354 | 295 | 260 | 247 | 225 |
Shares Outstanding (Diluted) | 761 | 354 | 295 | 260 | 247 | 225 |
Shares Change | 135.82% | 19.97% | 13.23% | 5.63% | 9.55% | 26.42% |
EPS (Basic) | -0.02 | -0.06 | -0.05 | -0.08 | -0.09 | -0.07 |
EPS (Diluted) | -0.02 | -0.06 | -0.05 | -0.08 | -0.09 | -0.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -8.83 | -9.48 | -13.84 | -15.07 | -17.77 | -15.68 |
Free Cash Flow Per Share | -0.01 | -0.03 | -0.05 | -0.06 | -0.07 | -0.07 |
Gross Margin | -28.91% | -17.10% | 33.82% | -18.66% | -15.66% | 5.33% |
Operating Margin | -669.53% | -1090.97% | -522.71% | -906.68% | -2448.13% | -1651.83% |
Profit Margin | -1123.44% | -1444.04% | -497.03% | -920.95% | -2083.19% | -1481.93% |
Free Cash Flow Margin | -766.06% | -701.63% | -483.72% | -689.34% | -1706.82% | -1547.48% |
EBITDA | -6.11 | -13.11 | -14.1 | -18.68 | -24.39 | -15.88 |
D&A For EBITDA | 1.61 | 1.63 | 0.86 | 1.14 | 1.1 | 0.86 |
EBIT | -7.71 | -14.74 | -14.96 | -19.82 | -25.49 | -16.73 |